Therapeutic Approaches for the Treatment of Interstitial Lung Disease: An Exploratory Review on Molecular Mechanisms

Overview

Journal Mini Rev Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2023 Aug 17

PMID 37587813

Authors

Revati Amin

Ruchi Pandey

K Vaishali

Vishak Acharya

Mukesh Kumar Sinha

Nitesh Kumar

Affiliations

Soon will be listed here.

Abstract

Background: Interstitial Lung Diseases (ILDs) are characterized by shortness of breath caused by alveolar wall inflammation and/or fibrosis.

Objective: Our review aims to study the depth of various variants of ILD, diagnostic procedures, pathophysiology, molecular dysfunction and regulation, subject and objective assessment techniques, pharmacological intervention, exercise training and various modes of delivery for rehabilitation.

Method: Articles are reviewed from PubMed and Scopus and search engines.

Results: ILD is a rapidly progressing disease with a high mortality rate. Each variant has its own set of causal agents and expression patterns. Patients often find it challenging to self-manage due to persistent symptoms and a rapid rate of worsening. The present review elaborated on the pathophysiology, risk factors, molecular mechanisms, diagnostics, and therapeutic approaches for ILD will guide future requirements in the quest for innovative and tailored ILD therapies at the molecular and cellular levels.

Conclusion: The review highlights the rationale for conventional and novel therapeutic approaches for better management of ILD.

References

Ryerson C, Urbania T, Richeldi L, Mooney J, Lee J, Jones K . Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2012; 42(3):750-7. DOI: 10.1183/09031936.00131912. View

Travis W, Costabel U, Hansell D, King Jr T, Lynch D, Nicholson A . An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013; 188(6):733-48. PMC: 5803655. DOI: 10.1164/rccm.201308-1483ST. View

Dillingh M, van den Blink B, Moerland M, van Dongen M, Levi M, KleinJan A . Recombinant human serum amyloid P in healthy volunteers and patients with pulmonary fibrosis. Pulm Pharmacol Ther. 2013; 26(6):672-6. DOI: 10.1016/j.pupt.2013.01.008. View

Glass D, Grossfeld D, Renna H, Agarwala P, Spiegler P, DeLeon J . Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J. 2022; 16(2):84-96. PMC: 9060042. DOI: 10.1111/crj.13466. View

Richeldi L, Costabel U, Selman M, Kim D, Hansell D, Nicholson A . Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365(12):1079-87. DOI: 10.1056/NEJMoa1103690. View

Serra Lopez-Matencio J, Gomez M, Vicente-Rabaneda E, Gonzalez-Gay M, Ancochea J, Castaneda S . Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. Pharmaceuticals (Basel). 2021; 14(8). PMC: 8400767. DOI: 10.3390/ph14080819. View

Vancheri C, Kreuter M, Richeldi L, Ryerson C, Valeyre D, Grutters J . Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2017; 197(3):356-363. DOI: 10.1164/rccm.201706-1301OC. View

ORiordan T, Smith V, Raghu G . Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. Chest. 2015; 148(4):1083-1092. DOI: 10.1378/chest.14-3218. View

Steele M, Schwartz D . Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med. 2012; 64:265-76. DOI: 10.1146/annurev-med-042711-142004. View

10.

Klingberg F, Chow M, Koehler A, Boo S, Buscemi L, Quinn T . Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation. J Cell Biol. 2014; 207(2):283-97. PMC: 4210443. DOI: 10.1083/jcb.201402006. View

11.

Sgalla G, Cocconcelli E, Tonelli R, Richeldi L . Novel drug targets for idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2016; 10(4):393-405. DOI: 10.1586/17476348.2016.1152186. View

12.

Mora A, Bueno M, Rojas M . Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis. J Clin Invest. 2017; 127(2):405-414. PMC: 5272191. DOI: 10.1172/JCI87440. View

13.

Bueno M, Lai Y, Romero Y, Brands J, St Croix C, Kamga C . PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis. J Clin Invest. 2015; 125(2):521-38. PMC: 4319413. DOI: 10.1172/JCI74942. View

14.

Larson-Casey J, Deshane J, Ryan A, Thannickal V, Carter A . Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis. Immunity. 2016; 44(3):582-596. PMC: 4794358. DOI: 10.1016/j.immuni.2016.01.001. View

15.

Cheresh P, Morales-Nebreda L, Kim S, Yeldandi A, Williams D, Cheng Y . Asbestos-induced pulmonary fibrosis is augmented in 8-oxoguanine DNA glycosylase knockout mice. Am J Respir Cell Mol Biol. 2014; 52(1):25-36. PMC: 4370253. DOI: 10.1165/rcmb.2014-0038OC. View

16.

Singh S, Collins B, Sharma B, Joshi J, Talwar D, Katiyar S . Interstitial Lung Disease in India. Results of a Prospective Registry. Am J Respir Crit Care Med. 2016; 195(6):801-813. DOI: 10.1164/rccm.201607-1484OC. View

17.

Richeldi L, Collard H, Jones M . Idiopathic pulmonary fibrosis. Lancet. 2017; 389(10082):1941-1952. DOI: 10.1016/S0140-6736(17)30866-8. View

18.

Raghu G, Rochwerg B, Zhang Y, Garcia C, Azuma A, Behr J . An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192(2):e3-19. DOI: 10.1164/rccm.201506-1063ST. View

19.

Sese L, Nunes H, Cottin V, Sanyal S, Didier M, Carton Z . Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. Thorax. 2017; 73(2):145-150. DOI: 10.1136/thoraxjnl-2017-209967. View

20.

Kaur A, Mathai S, Schwartz D . Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment. Front Med (Lausanne). 2017; 4:154. PMC: 5622313. DOI: 10.3389/fmed.2017.00154. View